BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Denufosol tetrasodium: Phase III data

In the double-blind, international Phase III TIGER-2 trial in 466 CF patients, denufosol missed the primary endpoint of significantly improving FEV1 at 48 weeks vs. placebo (40 vs. 32 mL, p=0.742). Denufosol also missed the secondary endpoints of rate of change in FEV1 at 48 weeks (-2.3% vs. -3.02%, p=0.41), change from baseline in FEF at 48 weeks (-0.034 vs. -0.018 L/sec, p=0.728) and time to...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >